Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Depression

156 clinical trials

120 products

3 drugs

Product
NEUROPHARMAGEN
Product
Desvenlafaxine succinate
Clinical trial
A Multicenter, Randomized, 8-Week Double-Blind Acute Phase Followed By a 6-Month Continuation Phase (Open-Label Or Double-Blind) Study to Evaluate the Efficacy, Safety, and Tolerability of DVS SR Versus Escitalopram in Postmenopausal Women With Major Depressive Disorder
Status: Completed, Estimated PCD: 2008-02-01
Clinical trial
Randomised, Controlled, Parallel Clinical Trial on the Efficacy of Pharmacogenetic Information Obtained With NEUROFARMAGEN in the Treatment of Patients With Mental Disorders
Status: Completed, Estimated PCD: 2015-10-01
Product
Treatment As Usual
Product
Escitalopram
Product
SAGE-217
Clinical trial
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of SAGE-217 in the Treatment of Adult Subjects With Major Depressive Disorder
Status: Completed, Estimated PCD: 2019-09-24
Product
Placebo
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
Status: Completed, Estimated PCD: 2023-09-29
Product
TNX-601
Clinical trial
A Phase 3, Randomized, Double-Blind Study Comparing the Efficacy and Safety of SAGE-217 Plus an Antidepressant Versus Placebo Plus an Antidepressant in Adults With Major Depressive Disorder
Status: Completed, Estimated PCD: 2021-10-25
Product
Citalopram
Product
Duloxetine
Product
Desvenlafaxine
Product
Matching Placebo
Product
Sertraline
Clinical trial
An Open-Label, Phase 2a, Single Dose Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression
Status: Recruiting, Estimated PCD: 2024-11-01
Product
BPL-003
Clinical trial
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
Status: Completed, Estimated PCD: 2024-01-31
Product
Esketamine
Clinical trial
A Phase II, 6-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Trial With a Quetiapine Arm to Evaluate the Efficacy, Tolerability and Safety of Oral BI 1358894 in Patients With Major Depressive Disorder With Inadequate Response to Antidepressants.
Status: Completed, Estimated PCD: 2024-01-10
Product
Quetiapine
Product
BI 1358894
Clinical trial
A Phase II, 6-week, Multicenter, Randomized, Double Blind (Patient and Investigator) or Masked, Placebo Controlled, Dose-finding Trial to Evaluate the Efficacy, Tolerability, and Safety of Different Doses of Oral BI 1569912 as Adjunctive Therapy in MD
Status: Recruiting, Estimated PCD: 2025-08-12
Product
BI 1569912
Product
Psilocybin
Clinical trial
A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant Depression
Status: Recruiting, Estimated PCD: 2024-10-01
Product
Liafensine
Clinical trial
A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression
Status: Completed, Estimated PCD: 2024-02-06
Product
MIJ821
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Single Subcutaneous MIJ821 Injection in Addition to Standard of Care in Participants With Treatment-resistant Depression
Status: Completed, Estimated PCD: 2023-11-28
Clinical trial
Efficacy of Digital Problem Solving Application in Reduction of Anxiety, Depression and Substance Use Disorder Symptoms
Status: Not yet recruiting, Estimated PCD: 2026-11-01
Product
DSPT
Product
Seltorexant
Clinical trial
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
Status: Terminated, Estimated PCD: 2022-05-24
Clinical trial
A Double-blind, Randomized, Psychoactive Placebo-controlled, Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (28 mg, 56 mg and 84 mg) of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Subjects Assessed to be at Imminent Risk for Suicide
Status: Completed, Estimated PCD: 2023-03-31
Product
Midazolam
Product
Intranasal
Clinical trial
A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of JNJ-67953964 in Subjects With Major Depressive Disorder
Status: Completed, Estimated PCD: 2020-05-06
Product
SEP-4199
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of SEP-4199 for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression)
Status: Completed, Estimated PCD: 2020-04-23
Product
DGX-001
Product
Vortioxetine
Clinical trial
Phase 2a Multicenter Randomized Double-Blind Placebo-Controlled Study to Assess the Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing of REL-1017 as Adjunctive Therapy in the Treatment of Pts Diagnosed With MDD
Status: Completed, Estimated PCD: 2019-07-30
Clinical trial
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Adaptive Dose-Finding Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Subjects With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
Status: Completed, Estimated PCD: 2019-01-12
Clinical trial
Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 18 Years of Age
Status: Terminated, Estimated PCD: 2022-03-25
Product
REL-1017
Clinical trial
A 6-Month, Multicenter, Double-Blind, Randomized, Flexible-Dose, Parallel-Group Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Subjects With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
Status: Completed, Estimated PCD: 2019-06-13
Clinical trial
A 12-Month Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Effectiveness of SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression)
Status: Terminated, Estimated PCD: 2023-11-17
Clinical trial
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
Status: Completed, Estimated PCD: 2021-07-30
Product
Quetiapine XR
Product
Selective Serotonin Reuptake Inhibitor
Product
Serotonin-Norepinephrine Reuptake Inhibitor
Product
JNJ-42847922
Clinical trial
An Eight-week, Randomized, Double-blind, Two Parallel Groups, Study to Assess Clinical Response of Duloxetine 60 mg and 120 mg Per Day in Patients Hospitalized for Severe Depression
Status: Completed, Estimated PCD: 2008-08-26
Clinical trial
A Phase 1, Randomized, Double-blind, Placebo-controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of DGX-001 in Healthy Volunteers Followed by a Stress Exposure Resilience Panel
Status: Completed, Estimated PCD: 2022-11-06
Clinical trial
A Multicentric, Randomized, Double-Blind, Placebo- and Positive-Controlled 4-way Crossover Study to Evaluate the Effects of Single and Repeated Administration of Oral Seltorexant as an add-on Medication to an Antidepressant on On-Road Driving Performance in Participants With Major Depressive Disorder
Status: Completed, Estimated PCD: 2023-03-16
Product
Zopiclone
Clinical trial
The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression
Status: Completed, Estimated PCD: 2021-10-14
Clinical trial
A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects With Major Depressive Disorder With Anxious Distress
Status: Completed, Estimated PCD: 2019-02-04
Product
JNJ-67953964
Clinical trial
A Phase II 6-week, Randomized, Double-blinded, Placebo Controlled, Parallel Group Decentralised Clinical Trial to Evaluate Efficacy and Safety of Oral BI 1358894 in Patients With Major Depressive Disorder With Inadequate Response to Antidepressants
Status: Terminated, Estimated PCD: 2022-04-19
Product
AXS-05
Clinical trial
Evaluating the Effect of Length of Time on Selective Serotonin Reuptake Inhibitors (SSRIs) on the Response to Psilocybin-assisted Therapy in Individuals With Mild-moderate Major Depressive Disorder (MDD)
Status: Withdrawn, Estimated PCD: 2023-03-14
Clinical trial
Interventional, Randomized, Double-blind, Placebo-controlled, Active-reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years, With Major Depressive Disorder (MDD)
Status: Completed, Estimated PCD: 2022-01-21
Clinical trial
An Open-Label Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Major Depressive Disorder
Status: Completed, Estimated PCD: 2020-10-23
Product
JNJ-42165279
Clinical trial
An Exploratory, Multicenter, Placebo-controlled, Randomized, Double-blind Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Subjects With Major Depressive Disorder
Status: Completed, Estimated PCD: 2019-04-29
Product
NV-5138
Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-5138 in Adults With Treatment Resistant Depression
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Fluoxetine
Product
Matched Placebo
Clinical trial
Randomized, Double-blind (Patient, Investigator), Placebo-controlled, Parallel Group, Single Dosing Study on Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of BI 1569912 as Adjunctive Therapy in Patients With Major Depressive Disorder
Status: Completed, Estimated PCD: 2023-11-16
Product
5 Methoxy N,N Dimethyltryptamine
Clinical trial
A Phase 1/2 Study of GH001 in Patients With Treatment-Resistant Depression
Status: Completed, Estimated PCD: 2021-11-06
Clinical trial
A Phase 2, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Oral Administration of Ganaxolone in Women With Postpartum Depression
Status: Completed, Estimated PCD: 2019-07-05
Product
Ganaxolone
Clinical trial
A Multi-region, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression)
Status: Terminated, Estimated PCD: 2023-10-18
Product
SEP-4199 CR
Product
SLS-002
Clinical trial
A 2-part Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) Administered to Adults With Major Depressive Disorder at Imminent Risk of Suicide
Status: Completed, Estimated PCD: 2023-06-17
Product
PCN-101
Clinical trial
A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of Intravenous PCN-101 in Treatment Resistant Depression
Status: Completed, Estimated PCD: 2022-11-10
Clinical trial
An Open-Label Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Treatment Resistant Depression
Status: Completed, Estimated PCD: 2022-03-04
Clinical trial
A Phase 2A, Double-blind, Placebo-controlled, Multiple-dose Escalation Study to Evaluate Safety, Pharmacokinetics and Efficacy of Intravenously Administered Ganaxolone in Women With Postpartum Depression
Status: Completed, Estimated PCD: 2019-05-10
Product
MK-1942
Clinical trial
A Phase 2a, Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-1942 Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression
Status: Terminated, Estimated PCD: 2023-09-08
Clinical trial
Double-Blind, Randomized, Parallel-Group Study With Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
Status: Completed, Estimated PCD: 2023-10-03
Clinical trial
A Quadruple Masked, Dose-Finding Study to Evaluate the Efficacy and Safety of Intranasal BPL-003 in Patients With Treatment Resistant Depression
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
The Role of Inflammation in Cognitive Dysfunction in Acute Depression as Determined by Experimental Inhibition of Tumor Necrosis Factor-alpha Signaling in a Randomized Controlled Trial.
Status: Not yet recruiting, Estimated PCD: 2027-09-01
Product
Infliximab
Clinical trial
Brain Network Dynamics of Depression During Esketamine Treatment
Status: Recruiting, Estimated PCD: 2024-08-30
Clinical trial
Sustained Mood Improvement With Laughing Gas Exposure: A Randomized Controlled Pilot Trial
Status: Completed, Estimated PCD: 2024-02-27
Product
Nitrous Oxide
Product
Oxygen + Midazolam
Clinical trial
Open Label Extension Study of Depressed Mood Improvement Through Nicotine (Depressed MIND3)
Status: Recruiting, Estimated PCD: 2025-10-31
Product
Nicotine patch
Clinical trial
Study on the Optimal Diagnosis and Treatment Strategy of Major Depressive Disorder Based on Anhedonia
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Escitalopram+Aripiprazole
Product
Escitalopram + Omega-3 PUFAs
Product
Escitalopram + Aripiprazole + Omega-3 PUFAs
Clinical trial
Combined N-of-1 Trials to Assess Open-Label Placebo Treatment for Antidepressant Discontinuation Symptoms
Status: Recruiting, Estimated PCD: 2024-06-01
Product
Open-label placebo
Clinical trial
A Phase II Randomized, Double-blind, Active Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Psilocybin in Treatment-resistant Major Depression
Status: Active (not recruiting), Estimated PCD: 2024-03-01
Product
Nicotinamide
Clinical trial
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
Status: Recruiting, Estimated PCD: 2032-12-01
Drug
Ketamine
Product
Perampanel
Clinical trial
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy and an Open-labeled Long-term Safety Extension Treatment With Seltorexant
Status: Completed, Estimated PCD: 2023-04-25
Clinical trial
ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)
Status: Completed, Estimated PCD: 2022-10-28
Clinical trial
Effects of Augmentation of Interpersonal Psychotherapy With High-Definition Transcranial Direct Current Stimulation for Adolescent Depression: A Randomized Clinical Trial
Status: Recruiting, Estimated PCD: 2024-12-31
Product
IPT plus HD-tDCS
Product
IPT
Clinical trial
Nicotinic Modulation of the Cognitive Control System in Late-life Depression
Status: Completed, Estimated PCD: 2022-10-07
Product
Transdermal Nicotine
Clinical trial
The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Feasibility Study of an HVR Protocol Biofeedback Training to Manage Long Covid Syndrome Symptoms
Status: Completed, Estimated PCD: 2023-10-30
Product
Treatment as usual
Clinical trial
OSU6162 as add-on in SSRI/SNRI-resistant Depression (ODEN): a Double-blind, Placebo-controlled Evaluation of Efficacy and Safety
Status: Recruiting, Estimated PCD: 2026-05-31
Product
OSU6162
Clinical trial
Clinical Predictors of Intravenous Ketamine Response in Treatment-Resistant Depression: A Randomized, Double-Blind, Midazolam-Controlled Pilot Study
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Stellate Ganglion Block for Major Depressive Disorder: A Randomized Controlled Pilot Trial
Status: Completed, Estimated PCD: 2022-02-10
Product
Bupivacaine
Clinical trial
The Effect of 2mg Sub-acute Prucalopride on Cognition and Emotional Processing in Participants Recovered From Depression
Status: Completed, Estimated PCD: 2023-11-13
Product
Prucalopride
Clinical trial
Psilocybin-assisted Psychotherapy in the Treatment of Patients Hospitalized for Treatment-resistant Depression: an Open-label Feasibility Study With an Experiential and Systemic Focus
Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Rivastigmine
Clinical trial
Improving Outcomes in Depression in Primary Care in a Low Resource Setting: Evidence From a Pilot Study
Status: Completed, Estimated PCD: 2024-03-10
Product
Antidepressant medication
Product
Normal Saline
Clinical trial
Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in Depression
Status: Not yet recruiting, Estimated PCD: 2027-08-01
Clinical trial
Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)
Status: Recruiting, Estimated PCD: 2028-02-01
Clinical trial
Serotonin-Norepinephrine Reuptake Inhibitors for the Prevention and Treatment of Pain, Depression, and Anxiety in Patients With Head & Neck Cancer
Status: Not yet recruiting, Estimated PCD: 2026-09-01
Product
Venlafaxine
Clinical trial
Effect of Intraoperative Esketamine Infusion on Depressive Symptoms of Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy
Status: Not yet recruiting, Estimated PCD: 2025-10-01
Product
Opioid
Clinical trial
The Role of Negr1 In Modulating Neuroplasticity in Major Depression (RONIN)
Status: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
The Efficacy and Safety of Esketamine for Rapid Treatment of Depressive Episodes With Suicidal Ideation in Mood Disorders: A Multicenter, Randomized Controlled Study
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
Central Versus Peripheral GABA and Glutamate Biomarkers for Treatment Response During Two Infusions of Intravenous Ketamine for Treatment-Resistant Depression
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
Effects of Pharmacological Dopamine Modulation on Motivation and Motor Function in Major Depression Characterized by Low-grade Inflammation.
Status: Recruiting, Estimated PCD: 2025-10-01
Product
L-dopa/Carbidopa
Clinical trial
CSP #590 - Lithium for Suicidal Behavior in Mood Disorders
Status: Terminated, Estimated PCD: 2019-08-13
Product
Lithium
Clinical trial
VA Aripiprazole vs. Esketamine for Treatment of Depression VAST-D II
Status: Withdrawn, Estimated PCD: 2023-10-27
Product
Aripiprazole
Clinical trial
Medication-assisted Psychotherapy: Using Ketamine-enhanced Radically Open Dialectical Behavior Therapy (RO DBT) to Target Neural and Behavioral Mechanisms of Action in Adults With Moderate to Severe Depression
Status: Recruiting, Estimated PCD: 2025-05-31
Product
Ketamine Infusion
Clinical trial
Safety and Pharmacokinetics of a Novel NMDA Receptor Antagonist Against Brain Related Diseases in Healthy Adult Volunteers: First-in-human, Phase I, Single Dose-escalating, Open Label Study
Status: Withdrawn, Estimated PCD: 2024-05-02
Product
Fluoroethylnormemantine
Clinical trial
Effects of Intranasal Oxytocin on Trust Towards Therapists and Dogs: A Randomized Controlled Trial in Healthy Adults
Status: Recruiting, Estimated PCD: 2024-08-31
Product
Oxytocin
Clinical trial
A Clinical Trial to Evaluate the Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Major Depressive Disorder
Status: Recruiting, Estimated PCD: 2024-03-04
Product
FMT oral Capsules
Clinical trial
Department of Nutrition, China Medical University
Status: Completed, Estimated PCD: 2023-06-30
Product
MIYAIRI 588
Clinical trial
Research and Application of Key Technologies for Early Identification, Risk Warning and Comprehensive Intervention of Adolescent Depression
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression
Status: Not yet recruiting, Estimated PCD: 2026-01-01
Product
Omega 3
Clinical trial
Does Psilocybin Require Psychedelic Effects to Treat Depression? A 4-Week, Double-Blind, Proof-of-Concept Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2026-02-01
Product
Risperidone
Drug
Varlilumab
Clinical trial
The Effects of Accelerated Intermittent Thetaburst Stimulation Followed by a Cognitive Control Training in Treatment Resistant Unipolar Depressed Patients
Status: Completed, Estimated PCD: 2023-12-31
Product
SSRI
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase 2b Trial With an Open-label Extension to Determine the Safety and Efficacy of GH001 in Patients With Treatment-resistant Depression
Status: Recruiting, Estimated PCD: 2024-06-01
Product
GH001
Clinical trial
RCT of Neurocognitive and Neuroimaging Biomarkers: Predicting Progression Towards Dementia in Patients With Treatment-resistant Late-life Depression (OPTIMUM-Neuro RCT)
Status: Active (not recruiting), Estimated PCD: 2024-04-30
Product
Bupropion
Clinical trial
Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
Status: Recruiting, Estimated PCD: 2027-06-29
Product
Genetic testing
Product
Nortriptyline
Clinical trial
Evaluation of the Antidepressant Effects of Nitrous Oxide in People With Major Depressive Disorder
Status: Recruiting, Estimated PCD: 2025-06-01
Product
Nitrous oxide
Clinical trial
Effects of Psilocybin With Psychological Support on Anhedonia in Treatment-resistant Depression: a Randomized Controlled Pilot Trial
Status: Not yet recruiting, Estimated PCD: 2025-03-01
Clinical trial
Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders
Status: Recruiting, Estimated PCD: 2025-05-01
Product
Dasatinib + Quercetin
Clinical trial
Combining Data Sources to Identify Effect Moderation for Personalized Mental Health
Status: Active (not recruiting), Estimated PCD: 2021-12-31
Clinical trial
Cognitive Behavioral Analysis System of Psychotherapy (CBASP) vs. Behavioral Activation (BA) in Persistently Depressed Treatment-resistant Inpatients: Efficacy, Moderators, and Mediators of Change
Status: Recruiting, Estimated PCD: 2024-07-01
Product
Algorithm-based study medication
Clinical trial
A Safe Ketamine-Based Therapy for Treatment Resistant Depression
Status: Completed, Estimated PCD: 2014-06-06
Clinical trial
Double-Blind Randomized Controlled Trial of Acute-Course of Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents
Status: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder
Status: Not yet recruiting, Estimated PCD: 2027-03-15
Product
Clonidine
Drug
placebo
Clinical trial
Salicylic Augmentation in Depression
Status: Terminated, Estimated PCD: 2021-02-16
Product
Aspirin
Clinical trial
The Effects of Citalopram on the Brain's Response to Faces
Status: Not yet recruiting, Estimated PCD: 2025-10-31
Clinical trial
Acute, Double-blind, Adaptively Randomized Treatment With Duloxetine or Escitalopram, Followed by Open-label Naturalistic Follow-up.
Status: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Psilocybin in Alcohol Use Disorder With Comorbid Depression
Status: Not yet recruiting, Estimated PCD: 2025-07-01
Clinical trial
Ketamine-Assisted Psychotherapy Viability in Treating Cancer-Related Emotional Distress
Status: Withdrawn, Estimated PCD: 2024-03-15
Product
Ketamine
Clinical trial
The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
Status: Recruiting, Estimated PCD: 2033-03-01
Clinical trial
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)
Status: Recruiting, Estimated PCD: 2025-04-01
Product
Inactive Placebo
Clinical trial
Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Precision Psychiatry: Anti-inflammatory Medication in Immuno-metabolic Depression
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Celecoxib
Clinical trial
Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Study 1.1. (Pharmacological Manipulation)
Status: Not yet recruiting, Estimated PCD: 2025-03-31
Product
Nociceptin Receptor Antagonist
Clinical trial
A Naturalistic Study of Ketamine for Treatment Resistant Mood Disorders: Gdansk Depression Ketamine Project
Status: Completed, Estimated PCD: 2022-07-04
Clinical trial
Mindfulness Engaged Neurostimulation for Depression
Status: Recruiting, Estimated PCD: 2026-04-30
Product
Medi-TBS
Clinical trial
Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-Resistant Depression: a Randomised, Rater-blinded Trial
Status: Recruiting, Estimated PCD: 2027-04-01
Product
Racemic ketamine
Clinical trial
A Pilot, Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of a Cannabis-Infused Oil For Treatment of Insomnia in Major Depression
Status: Recruiting, Estimated PCD: 2024-03-31
Product
25:1 CBD/THC
Product
5:1 CBD/THC
Clinical trial
Understanding the Safety of Home Ketamine Treatment Plans for Chronic Conditions
Status: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
Research on the Biological Mechanism of the Efficacy of Psychotherapy for Depression Based on the Near-Infrared Functional Imaging System (fNIRS)
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Antidepressant
Clinical trial
Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease
Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
Investigations on the Efficacy of Ketamine in Depression in Comparison to Electroconvulsive Therapy
Status: , Estimated PCD: 2025-12-01
Clinical trial
An Adaptive Algorithm-Based Approach to Treatment for Adolescent Depression
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Randomised, Controlled Trial to Investigate the Effect of a Sixweek Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Status: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
Neural and Antidepressant Effects of Propofol
Status: Active (not recruiting), Estimated PCD: 2022-12-31
Product
Propofol
Product
Second-line Antidepressants
Clinical trial
Precision Targeting of Propofol-induced Electroencephalographic Slow Waves: a Novel Phase I/2 Paradigm for Treatment-resistant Major Depressive Disorder
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Does the IMPase Inhibitor, Ebselen, Affect Emotional Processing and Brain Myo-inositol in Treatment-resistant Depression?
Status: Recruiting, Estimated PCD: 2024-05-31
Product
Ebselen
Clinical trial
Synaptic Imaging and Brain Network Activity Following Ketamine in Treatment Resistant Depression
Status: Recruiting, Estimated PCD: 2023-08-31
Clinical trial
Tianeptine for Treatment Resistant Depression
Status: Recruiting, Estimated PCD: 2025-06-01
Product
Tianeptine
Clinical trial
Comparative Efficacy of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment-resistant Unipolar Depression: A Randomized Controlled Trial.
Status: Recruiting, Estimated PCD: 2024-07-07
Product
Amantadine
Product
Pramipexole
Clinical trial
The Role of SNRI's in the Prophylaxis of Depression in the First Year Following Lower Extremity Fragility Fractures in Geriatric Patients
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
The Efficacy and Tolerability of Psilocybin in Participants With Treatment-Resistant Depression: a Phase 2, Randomized Feasibility Study
Status: Completed, Estimated PCD: 2023-07-22
Clinical trial
Substance Misuse To Psychiatric Disorders for Cannabis (SToP-C)--an Early Assertive Pharmacotherapy Intervention Pilot Study
Status: Completed, Estimated PCD: 2023-02-28
Clinical trial
Simvastatin add-on to Escitalopram in Patients With Comorbid Obesity and Major Depression: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial
Status: Recruiting, Estimated PCD: 2025-02-01
Product
Simvastatin
Clinical trial
Electroconvulsive Therapy and Concomitant Lithium in Depression: a Double-blind Randomized Controlled Pilot Study
Status: Active (not recruiting), Estimated PCD: 2025-05-30
Clinical trial
Intravenous Sub-anesthetic Ketamine Treatment in Treatment-Resistant Depression
Status: Completed, Estimated PCD: 2018-10-22
Product
midazolam
Clinical trial
Experimental Model of Depression in Aging: Insomnia, Inflammation, and Affect Mechanisms
Status: Recruiting, Estimated PCD: 2023-05-30
Product
Endotoxin
Clinical trial
Increasing Retention in Methadone Maintenance Treatment: Feasibility and Preliminary Efficacy of Ketamine for the Treatment of Patients With OUD and Comorbid Depression (OUDCD)
Status: Terminated, Estimated PCD: 2023-11-17
Clinical trial
Optimizing Placebo Effects in Depressed Older Adults: Enhancing Processing Speed and Executive Functioning With Computerized Cognitive Training
Status: Withdrawn, Estimated PCD: 2023-01-31
Product
Open-label Antidepressant Treatment
Clinical trial
Reward Emotion Learning and Ketamine Study
Status: Recruiting, Estimated PCD: 2023-05-01
Clinical trial
Investigating Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine
Status: Completed, Estimated PCD: 2023-02-13
Product
Naltrexone
Clinical trial
VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaL
Status: Active (not recruiting), Estimated PCD: 2021-12-31
Product
Omega-3 Fatty Acids
Clinical trial
Influence of Oxycodone on Individuals Taking an SSRI
Status: Not yet recruiting, Estimated PCD: 2025-01-15
Clinical trial
Preoperative Ketamine as a Strategy to Decrease Perioperative Depression During the Perioperative Period: a Randomized Active Controlled Pilot Study
Status: Withdrawn, Estimated PCD: 2023-02-02
Product
Oxycodone
Clinical trial
A Study of L-DOPA for Depression and Slowing in Older Adults
Status: Completed, Estimated PCD: 2018-09-14
Product
Levodopa
Clinical trial
Precision Medicine With Ketamine for Older Adults With Treatment-resistant Depression: Pilot Study
Status: Completed, Estimated PCD: 2021-11-30
Clinical trial
Combination Treatment With L-DOPA and Exercise for Mood and Mobility Problems in Late-Life
Status: Terminated, Estimated PCD: 2021-12-31
Product
Carbidopa/levodopa
Clinical trial
A Short-term Exploratory Study to Evaluate Safety, Tolerability and Pharmacokinetics of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to SSRI Monotherapy and Psychotherapy
Status: Terminated, Estimated PCD: 2024-04-08
Clinical trial
An Investigation of the Antidepressant Effects of the mGlu2/3 Receptor Antagonist TS-161 in Treatment-Resistant Depression
Status: Recruiting, Estimated PCD: 2024-06-03
Product
TS-161
Clinical trial
A Randomized, Double-Blind, Support-of-Concept Phase 2 Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD)
Status: Completed, Estimated PCD: 2022-06-28
Product
Niacin
Clinical trial
Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial
Status: Completed, Estimated PCD: 2023-03-08
Clinical trial
Dopaminergic Dysfunction in Late-Life Depression
Status: Recruiting, Estimated PCD: 2025-04-30
Product
L-Dopa
Clinical trial
Inhaled Nitrous Oxide for Acute Suicidality and Depression in the Emergency Department
Status: Not yet recruiting, Estimated PCD: 2025-10-01
Clinical trial
Induction Protocol for Psilocybin-Assisted Therapy in Treatment-Resistant Depression (TRD): A Pilot Study
Status: Recruiting, Estimated PCD: 2025-09-01
Product
psilocybin
Clinical trial
University of Iowa Interventional Psychiatry Service Patient Registry
Status: Recruiting, Estimated PCD: 2050-08-01
Clinical trial
An Open Label Trial of Inhaled N,N-Dimethyltryptamine in Patients With Partial Response in Depression.
Status: Completed, Estimated PCD: 2024-01-15
Product
N,N-Dimethyltryptamine
Clinical trial
An Open-Label Clinical Trial of Simultaneous Administration of Oral Aspirin and Ketamine as Adjunct to Oral Antidepressant Therapy in Treatment-Resistant Depression
Status: Completed, Estimated PCD: 2024-05-17
Product
VTS-K
Clinical trial
A Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
Status: Recruiting, Estimated PCD: 2024-09-18
Product
Aticaprant
Clinical trial
A Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
Status: Recruiting, Estimated PCD: 2024-10-17
Clinical trial
An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants With Major Depressive Disorder (MDD)
Status: Recruiting, Estimated PCD: 2025-10-22
Clinical trial
Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Integrated Internet-Based Cognitive Behavioural Therapy (i-CBT) and Intravenous Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Implementation Research on the Intervention Mode of " Comorbidity-Co-causes-Joint-prevention" Comprehensive Demonstration District of Depression and Obesity Among Children and Adolescents in Beijing
Status: Not yet recruiting, Estimated PCD: 2026-12-31
Product
Combination Intervention Strategy
Product
Routine Health Education and Mental Health Knowledge